{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:34:41Z","timestamp":1794893681237,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA100632"],"award-info":[{"award-number":["CA100632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA206210"],"award-info":[{"award-number":["CA206210"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["1UL1TR003167"],"award-info":[{"award-number":["1UL1TR003167"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["CA227064"],"award-info":[{"award-number":["CA227064"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["1UL1TR003167"],"award-info":[{"award-number":["1UL1TR003167"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["CA227064"],"award-info":[{"award-number":["CA227064"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["CA227064"],"award-info":[{"award-number":["CA227064"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP120348"],"award-info":[{"award-number":["RP120348"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170002"],"award-info":[{"award-number":["RP170002"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Grant, the Leukemia & Lymphoma Society through its Therapy Acceleration Program (TAP), and the MD Anderson Moon Shots program.","id":[{"id":"https:\/\/ror.org\/04m0xav37","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41591-022-02103-8","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T12:04:49Z","timestamp":1674129889000},"page":"115-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":435,"title":["Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6670-6792","authenticated-orcid":false,"given":"Mikhila","family":"Mahendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-8650","authenticated-orcid":false,"given":"Jixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kamiya-Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-9298","authenticated-orcid":false,"given":"Meghan E.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Emilia Di","family":"Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-0419","authenticated-orcid":false,"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Gera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-4798","authenticated-orcid":false,"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maro","family":"Ohanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyun A.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4895","authenticated-orcid":false,"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-8952","authenticated-orcid":false,"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi B.","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tiziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3166-8922","authenticated-orcid":false,"given":"Timothy P.","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Vellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cobi J.","family":"Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Kavelaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-3209","authenticated-orcid":false,"given":"Joseph R.","family":"Marszalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","volume":"36","author":"I Baccelli","year":"2019","unstructured":"Baccelli, I. et al. Mubritinib targets the electron transport chain Complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell 36, 84\u201399 (2019).","journal-title":"Cancer Cell"},{"key":"2103_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40170-015-0138-0","volume":"3","author":"L Schockel","year":"2015","unstructured":"Schockel, L. et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab. 3, 11 (2015).","journal-title":"Cancer Metab."},{"key":"2103_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fendo.2018.00372","volume":"9","author":"S Andrzejewski","year":"2018","unstructured":"Andrzejewski, S., Siegel, P. M. & St-Pierre, J. Metabolic profiles associated with metformin efficacy in cancer. Front. Endocrinol. (Lausanne) 9, 372 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2103_CR4","doi-asserted-by":"publisher","first-page":"115307","DOI":"10.1016\/j.bmc.2020.115307","volume":"28","author":"K Kuramoto","year":"2020","unstructured":"Kuramoto, K. et al. Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer. Bioorg. Med. Chem. 28, 115307 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"2103_CR5","doi-asserted-by":"publisher","first-page":"14276","DOI":"10.1021\/acs.jmedchem.0c01013","volume":"63","author":"Y Xu","year":"2020","unstructured":"Xu, Y., Xue, D., Bankhead, A. 3rd & Neamati, N. Why all the fuss about oxidative phosphorylation (OXPHOS)? J. Med. Chem. 63, 14276\u201314307 (2020).","journal-title":"J. Med. Chem."},{"key":"2103_CR6","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1200\/JCO.2020.38.15_suppl.3590","volume":"38","author":"SY Rha","year":"2020","unstructured":"Rha, S. Y. et al. Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 38, 3590\u20133590 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2103_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","volume":"162","author":"LB Sullivan","year":"2015","unstructured":"Sullivan, L. B. et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating Cells. Cell 162, 552\u2013563 (2015).","journal-title":"Cell"},{"key":"2103_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/nm.4399","volume":"23","author":"EM Kuntz","year":"2017","unstructured":"Kuntz, E. M. et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat. Med. 23, 1234\u20131240 (2017).","journal-title":"Nat. Med."},{"key":"2103_CR9","doi-asserted-by":"publisher","first-page":"e20200924","DOI":"10.1084\/jem.20200924","volume":"218","author":"L Stuani","year":"2021","unstructured":"Stuani, L. et al. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J. Exp. Med. 218, e20200924 (2021).","journal-title":"J. Exp. Med."},{"key":"2103_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.taap.2008.08.013","volume":"233","author":"JA Dykens","year":"2008","unstructured":"Dykens, J. A. et al. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol. Appl. Pharmacol. 233, 203\u2013210 (2008).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2103_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges, H. R., Jones, A. J., Pollak, M. N. & Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462, 475\u2013487 (2014).","journal-title":"Biochem. J."},{"key":"2103_CR12","doi-asserted-by":"publisher","unstructured":"Janku, F. et al. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Invest. New Drugs https:\/\/doi.org\/10.1007\/s10637-022-01277-9 (2022).","DOI":"10.1007\/s10637-022-01277-9"},{"key":"2103_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/toxsci\/kfn092","volume":"104","author":"M Sanchez","year":"2008","unstructured":"Sanchez, M., Gastaldi, L., Remedi, M., Caceres, A. & Landa, C. Rotenone-induced toxicity is mediated by Rho-GTPases in hippocampal neurons. Toxicol. Sci. 104, 352\u2013361 (2008).","journal-title":"Toxicol. Sci."},{"key":"2103_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/81834","volume":"3","author":"R Betarbet","year":"2000","unstructured":"Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease. Nat. Neurosci. 3, 1301\u20131306 (2000).","journal-title":"Nat. Neurosci."},{"key":"2103_CR15","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1074\/jbc.M117.786442","volume":"292","author":"AP Trotta","year":"2017","unstructured":"Trotta, A. P. et al. Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition. J. Biol. Chem. 292, 11727\u201311739 (2017).","journal-title":"J. Biol. Chem."},{"key":"2103_CR16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10637-021-01112-7","volume":"39","author":"F Janku","year":"2021","unstructured":"Janku, F. et al. First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. Invest. New Drugs 39, 1348\u20131356 (2021).","journal-title":"Invest. New Drugs"},{"key":"2103_CR17","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036\u20131046 (2018).","journal-title":"Nat. Med."},{"key":"2103_CR18","doi-asserted-by":"publisher","first-page":"eabg4000","DOI":"10.1126\/sciadv.abg4000","volume":"7","author":"I Chung","year":"2021","unstructured":"Chung, I. et al. Cork-in-bottle mechanism of inhibitor binding to mammalian complex I. Sci. Adv. 7, eabg4000 (2021).","journal-title":"Sci. Adv."},{"key":"2103_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1172\/JCI38942","volume":"120","author":"I Samudio","year":"2010","unstructured":"Samudio, I. et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120, 142\u2013156 (2010).","journal-title":"J. Clin. Invest."},{"key":"2103_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329\u2013341 (2013).","journal-title":"Cell Stem Cell"},{"key":"2103_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1046\/j.1365-2141.1996.d01-1922.x","volume":"95","author":"J Boultwood","year":"1996","unstructured":"Boultwood, J. et al. Amplification of mitochondrial DNA in acute myeloid leukaemia. Br. J. Haematol. 95, 426\u2013431 (1996).","journal-title":"Br. J. Haematol."},{"key":"2103_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41591-018-0019-5","volume":"24","author":"Y Lissanu Deribe","year":"2018","unstructured":"Lissanu Deribe, Y. et al. Mutations in the SWI\/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat. Med. 24, 1047\u20131057 (2018).","journal-title":"Nat. Med."},{"key":"2103_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/apha.12311","volume":"213","author":"S Piel","year":"2015","unstructured":"Piel, S., Ehinger, J. K., Elmer, E. & Hansson, M. J. Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition. Acta Physiol. (Oxf.) 213, 171\u2013180 (2015).","journal-title":"Acta Physiol. (Oxf.)"},{"key":"2103_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.yrtph.2010.05.005","volume":"58","author":"K Bando","year":"2010","unstructured":"Bando, K. et al. Comparison of potential risks of lactic acidosis induction by biguanides in rats. Regul. Toxicol. Pharm. 58, 155\u2013160 (2010).","journal-title":"Regul. Toxicol. Pharm."},{"key":"2103_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"2103_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2214\/AJR.09.4110","volume":"195","author":"M Nishino","year":"2010","unstructured":"Nishino, M., Jagannathan, J. P., Ramaiya, N. H. & Van den Abbeele, A. D. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am. J. Roentgenol. 195, 281\u2013289 (2010).","journal-title":"Am. J. Roentgenol."},{"key":"2103_CR27","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1182\/bloodadvances.2020003661","volume":"5","author":"K Saito","year":"2021","unstructured":"Saito, K. et al. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition. Blood Adv. 5, 4233\u20134255 (2021).","journal-title":"Blood Adv."},{"key":"2103_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fnmol.2017.00284","volume":"10","author":"JR Deuis","year":"2017","unstructured":"Deuis, J. R., Dvorakova, L. S. & Vetter, I. Methods used to evaluate pain behaviors in rodents. Front. Mol. Neurosci. 10, 284 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"2103_CR29","doi-asserted-by":"crossref","unstructured":"Curzon P, Zhang M, Radek RJ, et al. The Behavioral Assessment of Sensorimotor Processes in the Mouse: Acoustic Startle, Sensory Gating, Locomotor Activity, Rotarod, and Beam Walking. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press\/Taylor & Francis; 2009. Chapter 8.","DOI":"10.1201\/NOE1420052343.ch8"},{"key":"2103_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nrneurol.2014.77","volume":"10","author":"GJ Bennett","year":"2014","unstructured":"Bennett, G. J., Doyle, T. & Salvemini, D. Mitotoxicity in distal symmetrical sensory peripheral neuropathies. Nat. Rev. Neurol. 10, 326\u2013336 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"2103_CR31","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/cncr.31248","volume":"124","author":"J Ma","year":"2018","unstructured":"Ma, J., Kavelaars, A., Dougherty, P. M. & Heijnen, C. J. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: targeting the source. Cancer 124, 2289\u20132298 (2018).","journal-title":"Cancer"},{"key":"2103_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neures.2018.08.014","volume":"139","author":"S Kiryu-Seo","year":"2019","unstructured":"Kiryu-Seo, S. & Kiyama, H. Mitochondrial behavior during axon regeneration\/degeneration in vivo. Neurosci. Res. 139, 42\u201347 (2019).","journal-title":"Neurosci. Res."},{"key":"2103_CR33","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/j.pain.0000000000000893","volume":"158","author":"K Krukowski","year":"2017","unstructured":"Krukowski, K. et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain 158, 1126\u20131137 (2017).","journal-title":"Pain"},{"key":"2103_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bbi.2021.12.005","volume":"100","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Ma, J., Trinh, R. T., Heijnen, C. J. & Kavelaars, A. An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway. Brain Behav. Immun. 100, 287\u2013296 (2022).","journal-title":"Brain Behav. Immun."},{"key":"2103_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/ars.2016.6633","volume":"26","author":"DL Kirkpatrick","year":"2017","unstructured":"Kirkpatrick, D. L. & Powis, G. Clinically evaluated cancer drugs inhibiting redox signaling. Antioxid. Redox Signal. 26, 262\u2013273 (2017).","journal-title":"Antioxid. Redox Signal."},{"key":"2103_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2016.05.006","volume":"68","author":"MK Jha","year":"2016","unstructured":"Jha, M. K., Lee, I. K. & Suk, K. Metabolic reprogramming by the pyruvate dehydrogenase kinase-lactic acid axis: linking metabolism and diverse neuropathophysiologies. Neurosci. Biobehav. Rev. 68, 1\u201319 (2016).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"2103_CR37","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1097\/j.pain.0000000000000290","volume":"156","author":"K Krukowski","year":"2015","unstructured":"Krukowski, K., Nijboer, C. H., Huo, X., Kavelaars, A. & Heijnen, C. J. Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-mu. Pain 156, 2184\u20132192 (2015).","journal-title":"Pain"},{"key":"2103_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pain.2006.01.037","volume":"122","author":"SJL Flatters","year":"2006","unstructured":"Flatters, S. J. L. & Bennett, G. J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122, 245\u2013257 (2006).","journal-title":"Pain"},{"key":"2103_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnmol.2017.00108","volume":"10","author":"MA Maj","year":"2017","unstructured":"Maj, M. A., Ma, J., Krukowski, K. N., Kavelaars, A. & Heijnen, C. J. Inhibition of mitochondrial p53 accumulation by PFT-mu prevents cisplatin-induced peripheral neuropathy. Front. Mol. Neurosci. 10, 108 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"2103_CR40","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.pain.2011.12.011","volume":"153","author":"WH Xiao","year":"2012","unstructured":"Xiao, W. H. & Bennett, G. J. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 153, 704\u2013709 (2012).","journal-title":"Pain"},{"key":"2103_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","volume":"238","author":"H Zheng","year":"2012","unstructured":"Zheng, H., Xiao, W. H. & Bennett, G. J. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp. Neurol. 238, 225\u2013234 (2012).","journal-title":"Exp. Neurol."},{"key":"2103_CR42","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev-biochem-070511-103700","volume":"82","author":"J Hirst","year":"2013","unstructured":"Hirst, J. Mitochondrial complex I. Annu. Rev. Biochem. 82, 551\u2013575 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"2103_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.expneurol.2010.03.028","volume":"224","author":"AH Schapira","year":"2010","unstructured":"Schapira, A. H. Complex I: inhibitors, inhibition and neurodegeneration. Exp. Neurol. 224, 331\u2013335 (2010).","journal-title":"Exp. Neurol."},{"key":"2103_CR44","unstructured":"Chinnery PF. Primary Mitochondrial Disorders Overview. 2000 Jun 8 [Updated 2021 Jul 29]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022."},{"key":"2103_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141\u2013162 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2103_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/emboj.2012.300","volume":"32","author":"WJ Koopman","year":"2013","unstructured":"Koopman, W. J., Distelmaier, F., Smeitink, J. A. & Willems, P. H. OXPHOS mutations and neurodegeneration. EMBO J. 32, 9\u201329 (2013).","journal-title":"EMBO J."},{"key":"2103_CR47","doi-asserted-by":"publisher","first-page":"e55845","DOI":"10.7554\/eLife.55845","volume":"9","author":"ZA Stephenson","year":"2020","unstructured":"Stephenson, Z. A. et al. Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I. eLife 9, e55845 (2020).","journal-title":"eLife"},{"key":"2103_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fcvm.2016.00025","volume":"3","author":"AW El-Hattab","year":"2016","unstructured":"El-Hattab, A. W. & Scaglia, F. Mitochondrial cardiomyopathies. Front. Cardiovasc. Med. 3, 25 (2016).","journal-title":"Front. Cardiovasc. Med."},{"key":"2103_CR49","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ijcard.2014.11.014","volume":"177","author":"J Finsterer","year":"2014","unstructured":"Finsterer, J. & Kothari, S. Cardiac manifestations of primary mitochondrial disorders. Int. J. Cardiol. 177, 754\u2013763 (2014).","journal-title":"Int. J. Cardiol."},{"key":"2103_CR50","doi-asserted-by":"crossref","unstructured":"Gillies, R. J., Robey, I. & Gatenby, R. A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49, 24S\u201342S Suppl. 2 (2008).","DOI":"10.2967\/jnumed.107.047258"},{"key":"2103_CR51","doi-asserted-by":"publisher","first-page":"14353","DOI":"10.1523\/JNEUROSCI.1910-15.2015","volume":"35","author":"MK Jha","year":"2015","unstructured":"Jha, M. K. et al. Metabolic connection of inflammatory pain: pivotal role of a pyruvate dehydrogenase kinase-pyruvate dehydrogenase-lactic acid axis. J. Neurosci. 35, 14353\u201314369 (2015).","journal-title":"J. Neurosci."},{"key":"2103_CR52","doi-asserted-by":"publisher","first-page":"e139299","DOI":"10.1172\/JCI139299","volume":"131","author":"M Durante","year":"2021","unstructured":"Durante, M. et al. Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10. J. Clin. Invest. 131, e139299 (2021).","journal-title":"J. Clin. Invest."},{"key":"2103_CR53","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/mus.24724","volume":"52","author":"KM Ruzhansky","year":"2015","unstructured":"Ruzhansky, K. M. & Brannagan, T. H. 3rd Neuromuscular complications of hematopoietic stem cell transplantation. Muscle Nerve 52, 480\u2013487 (2015).","journal-title":"Muscle Nerve"},{"key":"2103_CR54","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00415-019-09372-3","volume":"266","author":"I Sakellari","year":"2019","unstructured":"Sakellari, I. et al. Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality. J. Neurol. 266, 1960\u20131972 (2019).","journal-title":"J. Neurol."},{"key":"2103_CR55","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00520-014-2225-0","volume":"22","author":"S Koeppen","year":"2014","unstructured":"Koeppen, S., Thirugnanasambanthan, A. & Koldehoff, M. Neuromuscular complications after hematopoietic stem cell transplantation. Support Care Cancer 22, 2337\u20132341 (2014).","journal-title":"Support Care Cancer"},{"key":"2103_CR56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/bmt.2017.239","volume":"53","author":"MR Dowling","year":"2018","unstructured":"Dowling, M. R. et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transpl. 53, 199\u2013206 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"2103_CR57","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.bbmt.2007.07.013","volume":"13","author":"D Siegal","year":"2007","unstructured":"Siegal, D. et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol. Blood Marrow Transpl. 13, 1369\u20131379 (2007).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2103_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-4939-1875-1_3","volume":"1241","author":"JP Rooney","year":"2015","unstructured":"Rooney, J. P. et al. PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol. Biol. 1241, 23\u201338 (2015).","journal-title":"Methods Mol. Biol."},{"key":"2103_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0024-z","volume":"1","author":"A Lodi","year":"2017","unstructured":"Lodi, A. et al. Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism. NPJ Precis. Oncol. 1, 18 (2017).","journal-title":"NPJ Precis. Oncol."},{"key":"2103_CR60","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.1002\/jcp.30307","volume":"236","author":"SM Stanford","year":"2021","unstructured":"Stanford, S. M. et al. The low molecular weight protein tyrosine phosphatase promotes adipogenesis and subcutaneous adipocyte hypertrophy. J. Cell. Physiol. 236, 6630\u20136642 (2021).","journal-title":"J. Cell. Physiol."},{"key":"2103_CR61","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S. et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 35, D521\u2013D526 (2007).","journal-title":"Nucleic Acids Res."},{"key":"2103_CR62","doi-asserted-by":"publisher","first-page":"W423","DOI":"10.1093\/nar\/gkn282","volume":"36","author":"S Okuda","year":"2008","unstructured":"Okuda, S. et al. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res. 36, W423\u2013W426 (2008).","journal-title":"Nucleic Acids Res."},{"key":"2103_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-019-5953-1","volume":"20","author":"HP Chao","year":"2019","unstructured":"Chao, H. P. et al. Systematic evaluation of RNA-Seq preparation protocol performance. BMC Genomics 20, 571 (2019).","journal-title":"BMC Genomics"},{"key":"2103_CR64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"2103_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"2103_CR66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Series B Stat. Methodol."},{"key":"2103_CR67","doi-asserted-by":"publisher","first-page":"574","DOI":"10.12688\/f1000research.6925.1","volume":"4","author":"R Kolde","year":"2015","unstructured":"Kolde, R. & Vilo, J. GOsummaries: an R package for visual functional annotation of experimental data. F1000Res 4, 574 (2015).","journal-title":"F1000Res"},{"key":"2103_CR68","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1093\/bioinformatics\/btv289","volume":"31","author":"B Wang","year":"2015","unstructured":"Wang, B., Cunningham, J. M. & Yang, X. H. Seq2pathway: an R\/Bioconductor package for pathway analysis of next-generation sequencing data. Bioinformatics 31, 3043\u20133045 (2015).","journal-title":"Bioinformatics"},{"key":"2103_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","volume":"53","author":"SR Chaplan","year":"1994","unstructured":"Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55\u201363 (1994).","journal-title":"J. Neurosci. Methods"},{"key":"2103_CR70","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1073\/pnas.1913444117","volume":"117","author":"P Singhmar","year":"2020","unstructured":"Singhmar, P. et al. The fibroblast-derived protein PI16 controls neuropathic pain. Proc. Natl Acad. Sci. USA 117, 5463\u20135471 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2103_CR71","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1097\/j.pain.0000000000001667","volume":"160","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers. Pain 160, 2877\u20132890 (2019).","journal-title":"Pain"},{"key":"2103_CR72","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1097\/j.pain.0000000000001921","volume":"161","author":"G Laumet","year":"2020","unstructured":"Laumet, G. et al. Interleukin-10 resolves pain hypersensitivity induced by cisplatin by reversing sensory neuron hyperexcitability. Pain 161, 2344\u20132352 (2020).","journal-title":"Pain"},{"key":"2103_CR73","doi-asserted-by":"publisher","first-page":"e100701","DOI":"10.1371\/journal.pone.0100701","volume":"9","author":"QL Mao-Ying","year":"2014","unstructured":"Mao-Ying, Q. L. et al. The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoS ONE 9, e100701 (2014).","journal-title":"PLoS ONE"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02103-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02103-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02103-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T12:08:10Z","timestamp":1728734890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02103-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02103-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1506700\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.Y. is the Medical Director of the Institute for Applied Cancer Science (M.D Anderson Cancer Center), which has a commercial interest in DDR and other inhibitors (no. IACS30380\/ART0380 was licensed to Artios). T.A.Y.\u2019s research has been supported by Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, Vivace and Zenith; he has consulted for AbbVie, AstraZeneca, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, Boxer, Bristol-Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Clovis, Cybrexa, Diffusion, EMD Serono, F-Star, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Idience, Ignyta, I-Mab, ImmuneSensor, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER, Pfizer, Piper-Sandler, Prolynx, Repare, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs and ZielBio; he is a stockholder in Seagen. N.D. has received research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs and Agios. M.K. has received research funding from AbbVie, Genentech, F. Hoffman La Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, AstraZeneca, Rafael Pharmaceutical, Sanofi and Forty-Seven and has served in a consulting or advisory role for AbbVie, Genentech, F. Hoffman La Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji and Janssen. N.P. serves on the Board of Directors for the following: Dan\u2019s House of Hope; Consulting: AbbVie, Aptitude Health, Astellas Pharma US, Inc., Blueprint Medicines, Bristol-Myers Squibb, Celgene Corp, Cimeio Therapeutics AG, ClearView Healthcare Partners, CTI BioPharma, Dava Oncology, Immunogen, Incyte, Intellisphere, LLC., Novartis AG, Novartis Pharmaceuticals Corp, OncLive (Owned by Intellisphere, LLC), Patient Power, PharmaEssentia, Protagonist Therapeutics, Sanofi-aventis, Stemline Therapeutics, Inc. and Total CME; financial relationships (for example, Stock, Royalty, Gift, Employment or Business Ownership): Karger Publishers; Scientific\/Advisory Committee Member: Cancer.Net, CareDx, CTI BioPharma, EUSA Pharma, Inc., Novartis Pharmaceuticals Corp, Pacylex, PharmaEssentia; Speaker\/Preceptorship: AbbVie, Aplastic Anemia & MDS International Foundation, Curio Science LLC, Dava Oncology, Imedex, Magdalen Medical Publishing, Medscape, Neopharm, PeerView Institute for Medical Education, Physician Education Resource (PER), Physicians Education Resource (PER), Postgraduate Institute for Medicine, Stemline Therapeutics, Inc. F.M.-B. consults for AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd., DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman La Roche Ltd., GT Apeiron, Genentech Inc., Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd, Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor and Zymeworks; serves on the advisory committee for Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals and Zentalis; and has received honoraria from Chugai Biopharmaceuticals; leads clinical trials that are funded or sponsored by Aileron Therapeutics, Inc., AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences, Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc. and Taiho Pharmaceutical Co. P.B. recieves research funding from Incyte, BMS, CTI BioPharma, Constellation (now Morphosys), Kartos, Blueprint Medicines, Cogent Biosciences, Ionis, Pfizer, Astellas, NS Pharma and Promedior, and honoraria from Incyte, BMS, CTI BioPharma, Sierra Oncology (now GSK), Blueprint Medicines, Cogent Biosciences, Abbvie, Karyopharm, Pharma Essentia, Novartis, Constellation (now Morphosys) and Kartos. A.M.T. is funded by OBI Pharma, Agenus, Parker Institute for Cancer Immunotherapy, Tvardi Therapeutics, Tempus, IMMATICS; Consulting or Advisory Roles: Vincerx, Diaccurate, BrYet, NEX-I, Macrogenics and BioEclipse. J.R. serves on the advisory board of Peptomyc, Kelun Pharmaceuticals\/Klus Pharma, Ellipses Pharma, Molecular Partners and IONCTURA; receives research funding from Blueprint Medicines, Black Diamond Therapeutics, Merck Sharp & Dohme, Hummingbird, Yingli, Vall d\u2019Hebron Institute of Oncology\/Cancer Core Europe; receives clinical research support from Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GalxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bycicle Therapeutics, Merus, Curis, Bayer, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics and Mirati Linnaeus Therapeutics; and receives travel support from the European Society for Medical Oncology. IACS-010759 was developed by scientists at MD Anderson. If this drug becomes FDA approved and commercially available, MD Anderson will profit from its sale. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}